Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

被引：4
|
作者：
Marin, Ellen [1 ]
Scott, Sara [2 ]
Maples, Kathryn [3 ]
Joseph, Nisha S. [4 ]
Hofmeister, Craig C. [5 ]
Gupta, Vikas A. [5 ]
Dhodapkar, Madhav V. [5 ]
Kaufman, Jonathan L. [5 ]
Lonial, Sagar [6 ]
Nooka, Ajay K. [2 ]
机构：
[1] Emory Univ Hosp, Winship Canc Inst, Decatur, GA USA
[2] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Pfizer, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study
    Catamero, Donna
    Benito, Patricia Blazquez
    Shenoy, Samantha
    Chastain, Katherine
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S316
  • [42] Apoptotic Cells for the Prevention of Cytokine Release Syndrome (CRS) in CAR T-Cell Therapy
    Mevorach, Dror
    Amor, Veronique
    Shabat, Yehudith
    BLOOD, 2016, 128 (22)
  • [43] BlinatumomabElevation of liver enzymes and cytokine release syndrome (CRS) secondary to drug toxicity: case report
    Reactions Weekly, 2023, 1970 (1) : 76 - 76
  • [44] MANAGING CYTOKINE RELEASE SYNDROME IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
    Catamero, Donna
    Blazquez, Patricia
    Shenoy, Samantha
    Chastain, Katherine
    Kruyswijk, Sandy
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [45] Fulminant Skin GvHD With a Cytokine Pattern Resemblant of Cytokine Release Syndrome Successfully Treated With Multimodal Immunosuppression Including Tocilizumab
    Hellwig, Yuliya
    Yoo, Young E.
    Ress, Marie L.
    Andres, Oliver
    Braun, Matthias
    Schlegel, Paul G.
    Woelfl, Matthias
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 2033 - 2035
  • [46] Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome
    Puyo, Pablo Velasco
    Moreno, Lucas
    de Heredia, Cristina Diaz
    Riviere, Jacques G.
    Palacin, Pere Soler
    ANALES DE PEDIATRIA, 2020, 93 (02): : 132 - 133
  • [47] Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab
    Cho, C.
    Perales, M. A.
    BONE MARROW TRANSPLANTATION, 2016, 51 (12) : 1620 - 1621
  • [48] Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome A Cautionary Case Report
    Radbel, Jared
    Narayanan, Navaneeth
    Bhatt, Pinki J.
    CHEST, 2020, 158 (01) : E15 - E19
  • [49] Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
    Kotch, Chelsea
    Barrett, David
    Teachey, David T.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (08) : 813 - 822
  • [50] Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy
    Kurnik, Marko
    Peter, Fazarinc
    Matej, Podbregar
    IMMUNOTHERAPY, 2024, 16 (12) : 791 - 801
12345